Table 1.
Demographics of Included Studies (n = 14).
| Study | MINORS Score, % | Level of Evidence | Treatment Type | Outcome Measures Reported | No. of Patients | Location | Lesion Size (Range), cm2 | Age (Range), Years | Follow-up (Range), Years |
|---|---|---|---|---|---|---|---|---|---|
| Buchmann et al. (2012) 6 | 63% | RCS, Level IV | ACT-Cs | Satisfaction Scale, VAS, Rowe, ASES, CSS and MRI | 4 | 3H, 1G | 6.0 H 2.0 G |
29.3 (21-36) | 3.4 (0.9-5.9) |
| Camp et al. (2015) 1 | 56% | RCR, Level IV | OCA | SSV, Quick DASH, ASES, X-ray and MRI | 1 | G | 1.8 | 25 | 1 |
| Frank et al. (2010) 24 | 69% | RCS, Level IV | MFX | SST, ASES, VAS | 14 (15 shoulders) | 9H, 5G, 1B | H: 5.1 (1-7.8) G: 1.7 (0.4-3.8) |
37 (18-55) | 2.3 (1-7.4) |
| Hünnebeck et al. (2017) 17 | 75% | RCS, Level IV | MFX | Subjective evaluation, ROM, CMS, SSV, and DASH, X-ray | 32 | 18H, 2G, 12B | — b | 56 (37-74) |
8.8 (5.3-12.3) |
| Johnson et al. (1997) 5 | 50% | RCR, Level IV | OCA | X-ray | 1 | H | 3.1 | 19 | 3 |
| Kircher et al. (2009)18,a | 63% | RCS, Level IV | OAT | CSS, MRI | 3 | 3H | 1.2 (1.1-1.4) | 8.5 (7.6-9.0) | 8.8 (7.6-9.8) |
| Mima et al. (2016) 19 | 56% | RCR, Level IV | Fixation with poly-l-lactic acid pins | ASES, X-ray, CT, and MRI | 1 | H | 2.0 | 29 | 4 |
| Park et al. (2006) 2 | 56% | RCR, Level IV | OAT | Arthroscopic evaluation | 1 | H | 0.6 | 13 | 2.6 |
| Pham et al. (2017) 3 | 56% | RCR, Level IV | OAT | VAS, SSV, CSS, and MRI | 1 | H | 1.5 | 14 | 2.2 |
| Provencher et al. (2010) 4 | 56% | RCR, Level IV | OCA | VAS and ROM | 1 | B | — b | 25 | 1.3 |
| Riff et al. (2017) 20 | 69% | RCS, Level IV | OCA | VAS, ASES, SST, SF-12, and X-ray | 20 | 9H, 11B | 4.9 (1.8-7.1) | 24.8 (17-49) | 5.5 |
| Siebold et al. (2003) 21 | 81% | PCS, Level IV | MFX and periosteal flap | CSS, X-ray, MRI, and arthroscopic evaluation | 5 | 5H | 3.1 (2.3-4.0) | 32 (16-56) | 2.2 (2-2.6) |
| Slabaugh et al. (2010) 22 | 50% | RCR, Level IV | MFX | VAS and ASES score | 1 | H | 6.3 | Early 40s | — b |
| Wang et al. (2018) 23 | 75% | RCS, Level IV | MFX | VAS, SST, ASES, SANE, and SF-12 scores | 13 (14 shoulders) | 8H, 5G, 1B | H: 5.2 (4.0-7.8) G: 1.5 (1.0-3.8) |
36.3 (18-55) | 10.2 (8.5-15.8) |
ACT-Cs = autologous chondrocyte transplantation–collagen membrane seeding; ASES = American Shoulder and Elbow Surgeons shoulder score; B = bipolar humeral and glenoid lesion; CMS = Constant-Murley Score; CSS = Constant Shoulder Score; DASH = Disabilities of the Arm, Shoulder and Hand Score; G = isolated glenoid lesion; H = isolated humeral head lesion; MFX = microfracture; MRI, magnetic resonance imaging; OAT = osteochondral autologous transplantation; OCA = osteochondral allograft transplantation; RCS = retrospective case series; ROM = range of motion; SANE = Single Assessment Numeric Evaluation; SF-12 = Short Form–12 (Mental and Physical); SST = Simple Shoulder Test; SSV = Subjective Shoulder Value; VAS = visual analogue score for pain.
Includes only patients in the study which met inclusion criteria as others had a history of glenohumeral instability.
Not reported or unable to calculate.